Tonix Pharmaceuticals Holding Corp. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

SIGNIFICANT ACCOUNTING POLICIES (Tables)

SIGNIFICANT ACCOUNTING POLICIES (Tables)

9 Months Ended

Sep. 30, 2017

Schedule of maturities for marketable securities

The balance of marketable securities at September 30, 2017 and December 31, 2016 is as follows (in thousands):

	1 Year or Less
	September 30, 2017		December 31, 2016
U.S. treasury bonds	$	—	$	2,752
U.S. agency bonds		—		1,254
Certificates of deposit		—		3,174
Total	$	—	$	7,180

Schedule of accumulated other comprehensive income

The following table summarizes the changes in accumulated other comprehensive income by component (in thousands):

	Foreign Currency Translation Adjustment			Unrealized Gains (Losses) on available for sale securities		Total
Balance at December 31, 2016		(7	)		—		(7	)
Other comprehensive loss		(3	)		—		(3	)
Balance at September 30, 2017		(10	)		—		(10	)

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details